ONC - BeiGene, Ltd.
297.04
-17.320 -5.831%
Share volume: 503,414
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$314.36
-17.32
-0.06%
View ratios
| Fiscal Date | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|
| Fiscal Quarter | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 02-27-2025 | 05-07-2025 | 08-06-2025 | 11-06-2025 | 02-26-2026 | |
| Total revenue | 1.128 B | 1.117 B | 1.315 B | 1.412 B | 1.498 B | |
| Cost of revenue | 160.560 M | 165.002 M | 164.606 M | 196.510 M | 142.422 M | |
| Gross profit | 967.264 M | 952.277 M | 1.151 B | 1.216 B | 1.356 B | |
| -1.55% | 20.84% | 5.66% | 11.51% | |||
| Operating expenses | 1.047 B | 941.175 M | 1.063 B | 1.053 B | 1.171 B | |
| Selling general and admin | 504.677 M | 459.288 M | 537.913 M | 528.998 M | 555.290 M | |
| Research and development | 542.012 M | 481.887 M | 524.896 M | 523.662 M | 615.423 M | |
| Total expenses | 1.047 B | 941.175 M | 1.063 B | 1.053 B | 1.171 B | |
| -10.08% | 12.92% | -0.95% | 11.21% | |||
| Operating income | -79.425 M | 11.102 M | 87.885 M | 163.114 M | 185.035 M | |
| Ebit | -93.159 M | 15.052 M | 96.052 M | 144.135 M | 149.344 M | |
| Pretax income | -85.351 M | 20.900 M | 99.549 M | 147.164 M | 149.241 M | |
| -124.49% | 376.31% | 47.83% | 1.41% | |||
| Income tax | 66.530 M | 19.630 M | 5.229 M | 22.323 M | 82.739 M | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -151.881 M | 1.270 M | 94.320 M | 124.841 M | 66.502 M | |
| 100.84% | 7,326.77% | 32.36% | -46.73% |